US 2005/0032802 A1 · Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents

A compound having the Formula (Ia):

or pharmaceutically acceptable salts thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR1, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C, —CO0 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl;
with the proviso that the compound of Formula (Ia) is not:
10-Hydroxy-6-methoxy-1, 1,4a,7-tetramethyl-1H,4aH-phenanthrene-2,9-dione;
or
10-Hydroxy-7-hydroxymethyl-6-methoxy-1,1,4a-trimethyl-1H,4aH-phenanthrene-2,9-dione, or a pharmaceutically acceptable salt thereof;
and
with the further proviso that if (i) D is C—OH;
(ii) Q1 is ═O;
(iii) Q2 is ═O;
(iv) A is CH;
and (v) E is CR7 then R4 is not —CH3.

28 more elements

A compound having the Formula (Ib):

and pharmaceutically acceptable salts thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
the ring with positions A, B, D, and E is not aromatic;
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, ═O, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
and
each halogen is independently —F, —Cl, —Br or —I.
R13 is H, C1-C10 alkyl, aryl, or benzyl.

20 more elements

A compound having the Formula (Ic):

and pharmaceutically acceptable salts thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
Q1 is ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is at each occurance independently —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, ═O, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is at each occurance independently —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
and
each halogen is independently —F, —Cl, —Br or —I.
R13 is H, C1-C10 alkyl, aryl, or benzyl.

19 more elements

A compound having the Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR1, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11—OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl;
with the proviso that (a) if (i) D is C—OH, (ii) Q1 is ═O, (iii) Q2 is ═O, (iv) A is CH, and (v) E is CR7 then R4 is not —CH3;
and (b) if (i) E is C—OH, (ii) Q1 is ═O, (iii) Q2 is ═O, (iv) R10 is H, (v) B is CR4, (vi) D is CR5, (vii) R7 is CH3, and (viii) Q3 is —O— then A is not C—OH.

20 more elements

A compound having the Formula (IIb):

or a pharmaceutically acceptable salt thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
the ring with positions A, B, D, and E is not aromatic;
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, ═O, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR1, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

20 more elements

A compound having the Formula (IIc):

or a pharmaceutically acceptable salt thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
Q1 is ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is at each occurance independently —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, ═O, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is at each occurance independently —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

19 more elements

A compound having the Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1, Q2 and Q3 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R1, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
and
each halogen is independently —F, —Cl, —Br or —I.

15 more elements

A compound having the Formula (IIIb):

or a pharmaceutically acceptable salt thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
the ring with positions A, B, D, and E is not aromatic;
Q1, Q2 and Q3 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, ═O, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR1, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR1, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10(hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
and
each halogen is independently —F, —Cl, —Br or —I.

17 more elements

A compound having the Formula (IVa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1, Q2 and Q3 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR1, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

16 more elements

A compound having the Formula (IVb):

or a pharmaceutically acceptable salt thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
the ring with positions A, B, D, and E is not aromatic;
Q1, Q2 and Q3 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, ═O, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR1, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11, is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

18 more elements

A compound having the Formula (Va):

or a pharmaceutically acceptable salt thereof, wherein:
Q1, Q2 and Q3 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 oalkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR1, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10(hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

16 more elements

A compound having the Formula (Vb):

or a pharmaceutically acceptable salt thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
the ring with positions A, B, D, and E is not aromatic;
Q1, Q2 and Q3 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, ═O, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10(oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

18 more elements

A compound having the Formula (VIa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1 is CHOH, CH2, CHOR, where R is C1-C10 alkyl, aryl, —CH2OR1, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, —P(O)(OR11)2
Q2 is ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R1, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10(hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R13 is H, C1-C10 alkyl, aryl, or benzyl;
and
each halogen is independently —F, —Cl, —Br or —I.

19 more elements

A compound having the Formula (VIb):

or a pharmaceutically acceptable salt thereof, wherein:
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
the ring with positions A, B, D, and E is not aromatic;
Q1 is CHOH, CH2, CHOR, where R is C1-C10 alkyl, aryl, —CH2OR11, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, —P(O)(OR11)2
Q2 is ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, ═O, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R13 is H, C1-C10 alkyl, aryl, or benzyl;
and
each halogen is independently —F, —Cl, —Br or —I.

21 more elements

A compound having the Formula (VIIa):

or a pharmaceutically acceptable salt thereof;
wherein
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CH2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR1, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(OR11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and Rr is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I;
with the proviso that (a) if (i) D is C—OH, (ii) Q1 is ═O, (iii) Q2 is ═O, (iv) A is CH, and (v) E is CR7 then R4 is not —CH3;
and (b) if (i) B is C—CH3, (ii) Q1 is ═O, (iii) Q2 is ═O, (iv) R1 is CH3, (v) R2 is CH3, (vi) R7 is methyl, (vii) D is CH, and (viii) E is CH then R3 is not ethyl.

20 more elements

A compound having the Formula (VIIb):

or pharmaceutically acceptable salts thereof, wehrein,
a dashed line indicates that the bond between the atoms that are connected by the dashed line can be a single bond or a double bond;
the ring with positions A, B, D, and E is not aromatic;
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CH2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR11, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(OR11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, ═O, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

19 more elements

A method for treating cancer or neoplastic disease, comprising administering to a patient in need of such treatment or prevention an effective amount of a compound having the Formula (Ia):

or pharmaceutically acceptable salts thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR1, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R., is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for treating cancer or neoplastic disease, comprising administering to a patient in need of such treatment or prevention an effective amount of a compound having the Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR1, —OC(O)R11, —C(O)R1, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1, is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for treating cancer or neoplastic disease, comprising administering to a patient in need of such treatment or prevention an effective amount of a compound having the Formula (VIIa):

or a pharmaceutically acceptable salt thereof;
wherein
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CH2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR1, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(OR11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10 haloalkyl, C1-C10hydroxyalkyl, —C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

18 more elements

A method for inhibiting the growth of a cancer cell or neoplastic cell, comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or pharmaceutically acceptable salt of the compound having the Formula (Ia):

or pharmaceutically acceptable salts thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for inhibiting the growth of a cancer cell or neoplastic cell, comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or pharmaceutically acceptable salt of the compound having the Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR1, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11—OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10(hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for inhibiting the growth of a cancer cell or neoplastic cell, comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or pharmaceutically acceptable salt of the compound having the Formula (VIIa):

or a pharmaceutically acceptable salt thereof;
wherein
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CH2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR11, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(OR11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10(hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

18 more elements

A method for inducing cytotoxicity in a cancer cell or neoplastic cell, comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or pharmaceutically acceptable salt of the compound having the Formula (Ia):

or pharmaceutically acceptable salts thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1, is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for inducing cytotoxicity in a cancer cell or neoplastic cell, comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or pharmaceutically acceptable salt of the compound having the Formula (Ia):

or a pharmaceutically acceptable salt thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1, is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for inducing cytotoxicity in a cancer cell or neoplastic cell, comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or pharmaceutically acceptable salt of the compound having the Formula (VIIa):

or a pharmaceutically acceptable salt thereof;
wherein
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CH2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR11, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(OR11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR(, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —CL-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

18 more elements

A pharmaceutical composition comprising (i) an effective amount of a compound or pharmaceutically acceptable salt of the compound;

and (ii) a pharmaceutically acceptable carrier, wherein the compound is a compound of the Formula (Ia):
or pharmaceutically acceptable salts thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR1, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H. C1-C10 alkyl, aryl, or benzyl.

19 more elements

A pharmaceutical composition comprising (i) an effective amount of a compound or pharmaceutically acceptable salt of the compound;

and (ii) a pharmaceutically acceptable carrier, wherein the compound is a compound of the Formula (IIa):
or a pharmaceutically acceptable salt thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

19 more elements

A pharmaceutical composition comprising (i) an effective amount of a compound or pharmaceutically acceptable salt of the compound;

and (ii) a pharmaceutically acceptable carrier, wherein the compound is a compound of the Formula (VIIa):
or a pharmaceutically acceptable salt thereof;
wherein
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CH2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR11, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(OR11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

19 more elements

A method for treating a fungal infection, comprising administering to a patient in need of such treatment or prevention an effective amount of a compound or a pharmaceutically acceptable salt of the compound of Formula (Ia):

or pharmaceutically acceptable salts thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for treating a fungal infection, comprising administering to a patient in need of such treatment or prevention an effective amount of a compound or a pharmaceutically acceptable salt of the compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11—OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for treating a fungal infection, comprising administering to a patient in need of such treatment or prevention an effective amount of a compound or a pharmaceutically acceptable salt of the compound of Formula (VIIa):

or a pharmaceutically acceptable salt thereof;
wherein
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CR2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR11, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(0R11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic hetero cycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B. D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NR2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic hetero cycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(0R11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR11 s)2, —O-arylPO(0R15s)2, or —O-alkylarylPO(0R15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NR2, —SH, —S(O)NR2, —S(O)2NR2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl, a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl, a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

15 more elements

A method for inhibiting the growth of a fungus, comprising contacting the fungus with an effective amount of a compound or pharmaceutically acceptable salt of the compound of Formula (Ia):

or pharmaceutically acceptable salts thereof, wherein:
Q, and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for inhibiting the growth of a fungus, comprising contacting the fungus with an effective amount of a compound or pharmaceutically acceptable salt of the compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein:
Q1 and Q2 are independently ═O, ═S, ═NOR, ═NR, ═N—NHR, or ═N—N(R)2, where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is —O—, —S—, or —N(H)—;
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11—OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10 alkyl, C7-C12arylalkyl, C1-C10 aminoalkyl, C1-C10 haloalkyl, C1-C10 hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R10 is —H, —C1-C10 alkyl, —C3-C7 cycloalkyl, —C(O)C1-C10 alkyl, —C1-C10 (oxy)alkyl, —C(O)NH2, —C(O)NHR12, —C(O)N(R12)2, P(O)(OR13)2, or -aryl, wherein R10 is not P(O)(OR13)2 if Q3 is —N(H)— or —S—;
R1 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
each halogen is independently —F, —Cl, —Br or —I;
and
R13 is H, C1-C10 alkyl, aryl, or benzyl.

18 more elements

A method for inhibiting the growth of a fungus, comprising contacting the fungus with an effective amount of a compound or pharmaceutically acceptable salt of the compound of Formula (VIIa):

or a pharmaceutically acceptable salt thereof;
wherein
Q1 and Q2 are independently ═O, ═S, ═NR, ═NOR, ═N—NHR, or ═N—N(R)2 where R is —H, —C1-C10 alkyl, or -aryl;
Q3 is CHOH, CH2, CHOR where R is C1-C10 alkyl, aryl, —CH2OR11, —C(O)R11, —C(O)OR11, —C(O)OR11, —C(O)NR11, or —P(O)(OR11)2
R1 and R2 are independently —H, -halogen, -amino, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, (C3-C7) cycloalkyl, -aryl, C1-C10 (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R1, R2 and the carbon atom to which they are both attached are taken together to form a (C3-C7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;
A is N or CR3;
B is N or CR4;
D is N or CR5;
E is N or CR6, at least one of A, B, D and E being CR3, CR4, CR5 or CR6, respectively;
each R3, R4, R5 and R6 is independently —H, —OH, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCH2OR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —S(O)2NHR11, —SOR11, —S(O)2R11, —NHC(O)R11, —NHSOR11, NHS(O)2R11, —OPO(OR15)2, —O-arylPO(OR15)2, or —O-alkylarylPO(OR15)2 wherein R15 is H, —C1-C10alkyl, C7-C12arylalkyl, C1-C10aminoalkyl, C1-C10haloalkyl, C1-C10hydroxyalkyl, C1-C10 alkoxy;
R7 is —H, —C1-C10 alkyl, or —C1-C10 alkoxy;
R8 and R9 are each independently —H, -halogen, —CN, —NH2, —NO2, —COOH, —C(O)NH2, —SH, —S(O)NH2, —S(O)2NH2, —C1-C10 (oxy)alkyl, —C1-C10 alkyl, —C1-C10 alkoxy, —C1-C10 (hydroxy)alkyl, —C1-C10 (amino)alkyl, —C1-C10 (halo)alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, —(C3-C7) cycloalkyl, -aryl, —C1-C10 (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, —CH2OR11, —OCR11, —OC(O)R11, —C(O)R11, —OC(O)OR11, —OC(O)NR11, —C(O)OR11, —C(O)NR11, —OP(O)(OR11)2, —SR11, —SOR11, —S(O)2R11, —S(O)2NHR11, —NHSR11, —NHSOR11, or —NHS(O)2R11;
R8 is also —S(CH2)namino acid, —S(CH2)npeptide, wherein n=0 to 4, wherein the amino acid is connected to the compound through its alpha carbon atom, and wherein the peptide is connected to the compound through the alpha carbon atom of one of its amino acids;
R11 is —H, —C1-C10 alkyl, —(C3-C7) cycloalkyl, —C1-C10 (halo)alkyl, -aryl, —C2-C10 alkenyl, —C2-C10 alkynyl, —C1-C10 (aryl)alkyl, —C2-C10 (aryl)alkenyl, —C2-C10 (aryl)alkynyl, —C1-C10 (hydroxy)alkyl, —C1-C10 alkoxy, —C1-C10 (amino)alkyl,
a —(C3-C7) cycloalkyl unsubstituted or substituted with one or more —C1-C10 alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, or
a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more —C1-C10 alkyl, —C2-C10 alkenyl, or —C2-C10 alkynyl;
R12 is C1-C10 alkyl;
R14 is —H, —OH, or halogen;
and
each halogen is independently —F, —Cl, —Br or —I.

18 more elements

Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents

Life of this patent

Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents

Life of this patent

Abstract

Claims66